Can a simple timing change make leukemia therapy safer?

NCT ID NCT05519579

Recruiting now Disease control Sponsor: Northside Hospital, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a chemotherapy drug (methotrexate) into the spinal fluid before and during blinatumomab treatment can prevent nerve-related side effects in adults with acute lymphoblastic leukemia. The trial enrolls 20 people receiving their first cycle of blinatumomab. Researchers will track how many participants experience neurotoxicity and whether the leukemia responds to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: methotrexate and blinatumomab
What this could lead to: If it works, this could make a key leukemia treatment safer by reducing nerve-related side effects.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The approach may not reduce neurotoxicity as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Northside Hospital
RECRUITING

Atlanta, Georgia, 30342, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.